| Year |
Citation |
Score |
| 2022 |
Candito DA, Simov V, Gulati A, Kattar S, Chau RW, Lapointe BT, Methot JL, DeMong DE, Graham TH, Kurukulasuriya R, Keylor MH, Tong L, Morriello GJ, Acton JJ, Pio B, et al. Discovery and Optimization of Potent, Selective, and Brain-Penetrant 1-Heteroaryl-1-Indazole LRRK2 Kinase Inhibitors for the Treatment of Parkinson's Disease. Journal of Medicinal Chemistry. PMID 36475697 DOI: 10.1021/acs.jmedchem.2c01605 |
0.565 |
|
| 2018 |
Chen HY, Plummer CW, Xiao D, Chobanian HR, DeMong D, Miller M, Trujillo ME, Kirkland M, Kosinski D, Mane J, Pachanski M, Cheewatrakoolpong B, Di Salvo J, Thomas-Fowlkes B, Souza S, et al. Structure-Activity Relationship of Novel and Selective Biaryl-Chroman GPR40 AgoPAMs. Acs Medicinal Chemistry Letters. 9: 685-690. PMID 30034601 DOI: 10.1021/Acsmedchemlett.8B00149 |
0.32 |
|
| 2017 |
Scott JD, DeMong DE, Greshock TJ, Basu K, Dai X, Harris J, Hruza A, Li SW, Lin SI, Liu H, Macala MK, Hu Z, Mei H, Zhang H, Walsh P, et al. Discovery of a 3-(4-Pyrimidinyl) Indazole (MLi-2), an Orally Available and Selective Leucine-Rich Repeat Kinase 2 (LRRK2) Inhibitor that Reduces Brain Kinase Activity. Journal of Medicinal Chemistry. PMID 28245354 DOI: 10.1021/Acs.Jmedchem.7B00045 |
0.567 |
|
| 2015 |
Fell MJ, Mirescu C, Basu K, Cheewatrakoolpong B, DeMong DE, Ellis JM, Hyde LA, Lin Y, Markgraf CG, Mei H, Miller M, Poulet FM, Scott JD, Smith MD, Yin Z, et al. MLi-2, a potent, selective and centrally active compound for exploring the therapeutic potential and safety of LRRK2 kinase inhibition. The Journal of Pharmacology and Experimental Therapeutics. PMID 26407721 DOI: 10.1124/Jpet.115.227587 |
0.567 |
|
| 2014 |
DeMong D, Dai X, Hwa J, Miller M, Lin SI, Kang L, Stamford A, Greenlee W, Yu W, Wong M, Lavey B, Kozlowski J, Zhou G, Yang DY, Patel B, et al. The discovery of N-((2H-tetrazol-5-yl)methyl)-4-((R)-1-((5r,8R)-8-(tert-butyl)-3-(3,5-dichlorophenyl)-2-oxo-1,4-diazaspiro[4.5]dec-3-en-1-yl)-4,4-dimethylpentyl)benzamide (SCH 900822): a potent and selective glucagon receptor antagonist. Journal of Medicinal Chemistry. 57: 2601-10. PMID 24527772 DOI: 10.1021/Jm401858F |
0.38 |
|
| 2013 |
DeMong DE, Ng I, Miller MW, Stamford AW. A novel method for the preparation of 4-arylimidazolones. Organic Letters. 15: 2830-3. PMID 23713942 DOI: 10.1021/Ol401165E |
0.333 |
|
| 2007 |
Xia M, Hou C, DeMong DE, Pollack SR, Pan M, Brackley JA, Jain N, Gerchak C, Singer M, Malaviya R, Matheis M, Olini G, Cavender D, Wachter M. Synthesis, structure-activity relationship and in vivo antiinflammatory efficacy of substituted dipiperidines as CCR2 antagonists. Journal of Medicinal Chemistry. 50: 5561-3. PMID 17929797 DOI: 10.1021/Jm070902B |
0.358 |
|
| 2007 |
Xia M, Hou C, Pollack S, Brackley J, DeMong D, Pan M, Singer M, Matheis M, Olini G, Cavender D, Wachter M. Synthesis and biological evaluation of phenyl piperidine derivatives as CCR2 antagonists. Bioorganic & Medicinal Chemistry Letters. 17: 5964-8. PMID 17869105 DOI: 10.1016/j.bmcl.2007.07.065 |
0.369 |
|
| 2003 |
DeMong DE, Williams RM. Asymmetric synthesis of (2S,3R)-capreomycidine and the total synthesis of capreomycin IB. Journal of the American Chemical Society. 125: 8561-5. PMID 12848564 DOI: 10.1021/Ja0351241 |
0.541 |
|
| 2003 |
Williams RM, Sinclair PJ, DeMong DE, Chen D, Zhai D. Asymmetric synthesis of N-tert-butoxycarbonyl α-amino acids. Synthesis of (5S,6R)-4-tert-butoxycarbonyl-5,6-diphenylmorpholin-2-one (4-morpholinecarboxylic acid, 6-oxo-2,3-diphenyl-, 1,1-dimethylethyl ester, (2S,3R) Organic Syntheses. 80: 18-30. |
0.36 |
|
| 2002 |
DeMong DE, Williams RM. The first asymmetric synthesis of (2S)- and (2R)-amino-3,3-dimethoxypropanoic acid Tetrahedron Letters. 43: 2355-2357. DOI: 10.1016/S0040-4039(02)00269-1 |
0.547 |
|
| 2001 |
Jain RP, Albrecht BK, DeMong DE, Williams RM. Asymmetric synthesis of (+)-hypusine. Organic Letters. 3: 4287-9. PMID 11784199 DOI: 10.1021/Ol016959O |
0.58 |
|
| 2001 |
DeMong DE, Williams RM. The asymmetric synthesis of (2S,3R)-capreomycidine Tetrahedron Letters. 42: 3529-3532. DOI: 10.1016/S0040-4039(01)00487-7 |
0.559 |
|
| 2001 |
DeMong DE, Williams RM. An efficient asymmetric synthesis of (2S,3S)- and (2R,3R)-β-hydroxyornithine Tetrahedron Letters. 42: 183-185. DOI: 10.1016/S0040-4039(00)01945-6 |
0.565 |
|
| 2001 |
DeMong DE, Williams RM. ChemInform Abstract: An Efficient Asymmetric Synthesis of (2S,3S)- and (2R,3R)-β-Hydroxyornithine. Cheminform. 32: no-no. DOI: 10.1002/CHIN.200116195 |
0.342 |
|
| Show low-probability matches. |